- Teva Pharmaceuticals recalls 1-milligram, 2-milligram and 5-milligram Prazosin hydrochloride capsules.
- This is due to the medication containing high levels of carcinogenic impurity N-nitroso Prazosin C.
- While risk is low, replace your recalled blood pressure medication and talk to a healthcare provider.
There’s an active recall on blood pressure medication prescribed and sold nationwide, according to the U.S. Food and Drug Administration (FDA). This is due to high levels of “N-nitroso Prazosin impurity C” in the medication, which is a potential carcinogenic substance.
The recall applies to 1-milligram, 2-milligram and 5-milligram capsules of Prazosin hydrochloride, which is commonly prescribed to those as a treatment for high blood pressure (hypertension). Distributed by Teva Pharmaceuticals USA, the 100-capsule, 250-capsule, 500-capsule and 1000-capsule bottles have expiration dates ranging from October 2025 through February 2027.
Testing of these products found levels of the impurity “N-nitroso Prazosin impurity C” that were higher than the safety limit established by the Carcinogenic Potency Categorization Approach (CPCA). The recall occurred because the product did not meet manufacturing quality standards. Although the impurity poses a low cancer risk at small amounts, the detected levels exceeded safety limits and violated FDA manufacturing requirements. As a result, this recall was classified as a Class II recall, meaning consuming the recalled medication may lead to minor, temporary health problems.
Talk to a healthcare provider if you have questions or concerns about long-term use of the recalled medication. Return and replace any recalled Prazosin hydrochloride immediately. For questions about this recall, contact the FDA by calling 1-888-INFO-FDA (1-888-463-6332).
